Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XURIDEN vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xuriden (uridine triacetate) is a prodrug of uridine that restores intracellular uridine nucleotide pools, which are essential for RNA and DNA synthesis, thereby reversing the toxicity of fluorouracil (5-FU) and capecitabine overdose.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Emergency treatment of fluorouracil (5-FU) overdose,Emergency treatment of capecitabine overdose
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
60 mg/kg orally once daily, rounded to the nearest 60 mg increment. Maximum dose: 6000 mg/day.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h). Clinically relevant for dosing interval (every 6 hours).
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Xuriden is deacetylated by esterases in the plasma and tissues to release uridine, which is then further metabolized via the pyrimidine salvage pathway.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal: predominantly as intact uridine (47-62%) and uracil (16-25%); fecal/biliary: minimal (<5%).
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
<5% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Vd: 0.5-0.8 L/kg, indicating distribution into total body water.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Oral: approximately 60% (range 40-80%) due to first-pass metabolism.
Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Weight-based dosing: 60 mg/kg orally once daily. Maximum dose 6000 mg/day. Administer with food.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
No specific dose adjustment recommended. Use with caution due to age-related decline in renal function; monitor renal function periodically.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
None.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Not indicated for non-emergency use or as prophylaxis for chemotherapy.,Should be initiated as soon as possible after overdose, ideally within 96 hours.,May cause diarrhea, nausea, vomiting, and abdominal pain.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
None known.
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
Take with food to minimize gastrointestinal discomfort. No specific food restrictions; avoid excessive grapefruit juice as it may affect uridine metabolism.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of uridine triacetate during organogenesis produced teratogenic effects (neural tube defects, skeletal malformations) at doses 0.4 times the human dose based on body surface area. Risk cannot be ruled out. First trimester: potential for major malformations; second and third trimesters: potential for fetal growth impairment and neurodevelopmental effects.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
No data on presence in human milk, effects on breastfed infant, or milk production. Given the molecular weight of uridine triacetate (approximately 488 Da) and its metabolic conversion, excretion into breast milk is plausible. M/P ratio not determined. Use during breastfeeding only if clearly needed and consider alternatives or pump and discard.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Physiological changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce uridine triacetate exposure. No formal dosing adjustment studies; however, monitor clinical response and consider dose adjustment based on trough levels of uridine or clinical efficacy if available. No specific pregnancy-recommended dose adjustment from manufacturer.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Xuriden (uridine triacetate) is a pyrimidine analog used for hereditary orotic aciduria. Monitor for orotic acid crystalluria; ensure adequate hydration. Administer with food to reduce GI upset. Not recommended for use with fluorouracil or capecitabine due to interference.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
Take exactly as prescribed, usually once daily with food.,Do not crush or chew tablets; swallow whole.,Drink plenty of fluids to prevent kidney stones.,Report any signs of allergic reaction or severe abdominal pain.,Continue treatment even if feeling well; do not stop without consulting physician.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XURIDEN vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
XURIDEN is a Metabolic Agent that works by Xuriden (uridine triacetate) is a prodrug of uridine that restores intracellular uridine nucleotide pools, which are essential for RNA and DNA synthesis, thereby reversing the toxicity of fluorouracil (5-FU) and capecitabine overdose.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XURIDEN and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XURIDEN is: 60 mg/kg orally once daily, rounded to the nearest 60 mg increment. Maximum dose: 6000 mg/day.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XURIDEN and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XURIDEN is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of uridine triacetate during organogenesis produced teratogenic effec. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.